group researches the health related industries, primarily biotech and pharma, in India and abroad.
Such studies, both
quantitatve and qualitative, should prove useful to policy making that is
geared to supporting industrial innovation.
In addition we have a series of general articles in
Current Science entitled 'Bio-business in brief'. These articles
highlight different aspects of drug discovery and development, including institutional arrangements, that are possibly of interest to
scientists and policy researchers. We hope that they will contribute to a debate that is vital to producing a knowledge
driven industry, itself important to ensure a healthier India.
Kumari, S. and Saberwal, G.
maintenence by Indian pharma and bio-pharma companies.
Asian Biotechnology Development Review 15, 69-77 (2013)
Jaroslawski, S. and Saberwal, G.
Case studies of innovative medical device companies from India: Barriers and enablers to development.
BMC Health Services Research 13, 199-207 (2013)
Giving voice to India's entrepreneurs.
Nature Biotechnology 31, 104-107 (2013)
Marimuthu, G., Kumari, S.,
Kandasamy, M., Raghunathan, S. and Saberwal, G.
Patents protecting biologics or small molecule drugs are usually
Nature Biotechnology 30, 50-53 (2012)
Soby, S, Sebastian, T.E. and
US patent holdings of Indian non-corporate entities.
Asian Biotechnology Development Review 14, 21-33 (2012)
Soby, S., Kandasamy, M. and
Work outsourced to Indian biotech and pharma companies is not yet
Current Science 102, 401-404 (2012)
Sebastian, T.E., Pattnayak,
J.P., Soby, S and Saberwal, G.
Patent holdings of Indian pharmaceutical and biotechnology companies in
international markets of different sizes.
Asian Biotechnology Development Review 13, 17-37 (2011)
Seeding a skilled workforce.
Sebastian, T.E., Chandra Bindu,
Y. and Saberwal, G.
Patent holdings of US biotherapeutic companies in major markets.
14, 442-445 (2009)
Chandra Bindu, Y. , Mehdiratta, R. and Saberwal, G.
The US patent holdings of homegrown Indian biotech and pharma
Science 96, 252-259 (2009)
Mehdiratta, R. and Saberwal, G.
How many patents does a bio-therapeutics company need?
Biotechnology 26, 763-766 (2008)
New pharma-biotech company formation in India
24, 499-501 (2006)
SERIES OF ARTICLES IN CURRENT SCIENCE
Venkatachalam, S. and Saberwal, G
Bio-business in brief: A case for new drugs at generic prices from India
Science 102, 1375-1381 (2012)
Translating academic discoveries
Science 103, 767-769 (2012)
Bio-business in brief: A bit about technology transfer
Science 99, 177-180 (2010)
Bio-business in brief: The debate over biosimilars
Science 98, 1575-1578 (2010)
Bio-business in brief: The paradox of being a drug company
Science 97, 623-625
Devaguptapu, S, Mehdiratta, R
and Saberwal, G
Bio-business in brief: The case of Cytokinetics Inc.
Mehdiratta, R, Parida, D
K and Saberwal, G
Bio-business in brief: The challenges of clinical trials
Mehdiratta, R and Saberwal, G
Bio-business in brief: Many a monoclonal.
Science 93, 789-796 (2007)
Mehdiratta, R and Saberwal, G
Bio-business in brief: The case of conotoxins.
92, 39-45 (2007)
PERSPECTIVES AND OTHER
On being a professional mutant
Biotechnology (in press)
Caring for a severely disabled person.
Kapoor, M. and Saberwal, G
The new crossroads
Biotech News 5, 143-145 (2010)
Drug development in India: What does the future look like?
Contemporary Perspectives: History and Sociology of South Asia,
Ed. N Tyabji, 3, 293-309
A long march
News IV, 68-69 & 75 (2009)
Biotechnology Incubation in India. In Business incubation:
Initiatives in India Ed. R. K. Lagu, brought out by NSTEDB, DST
We have received generous
funding from the Wadhwani Foundation and the Institut Merieux to
support our research and